The Middle East and its position within World Health Organization regional offices
The Middle East is a term first used at the beginning of the last century [1] . It has a loose geographic definition, but with wealthy political usages [2] . Geographically, the Middle East is a region extending from the western side of the Indian subcontinent to the Eastern Mediterranean and from the Arabian Peninsula in the South to Turkey in the North. There are 16 countries forming the Middle East, namely Egypt, Iran, Iraq, Turkey, Saudi Arabia, Yemen, Syria, United Arab Emirates (UAE), Jordan, Palestine, Lebanon, Oman, Kuwait, Qatar, Bahrain, and Israel [3] . According to the World Health Organization (WHO) database, almost 400 million people, approximately 5% of the world's population, live in the Middle East: Egypt (90 million), Iran (78 million), Turkey (78 million), Iraq (35 million) and Saudi Arabia (31 million) being the most populated countries [4] . Six countries are in the Gulf Cooperation Council (GCC); Saudi Arabia, Qatar, Bahrain, Kuwait, Oman, and UAE [5] . Saudi Arabia is the biggest country among the GCC, followed by UAE (9.1 million), Oman (4.2 million), Kuwait (3.8 million), Qatar (2.2 million), and the smallest is Bahrain with population of 1.4 million [4] .
Historically, several civilizations and religions have been embraced in the Middle East and formed a framework for human interactions [6] . Some of the human interactions could have medical consequences, such as: waves of human migration and settlements; inter-marriage between civilizations; numerous wars and political instabilities; as well as trading and industry [3, 7, 8] . Since the beginning of 2011, uprisings and dramatic political changes have swept the Middle East, with major events occurring in Egypt, Syria, and some of the Gulf states and Yemen [2] . The effect of these events on the health systems needs to be addressed. Tuberculosis (TB) has been a familiar disease in the Middle East since ancient times [9] . A consistent external source of TB transmission is the substantial numbers of people migrating to the Middle East for economic or religious reasons [10] . Many of those immigrants or travelers are coming to the Middle East from countries that are endemic for multidrug-resistant (MDR) TB, such as South-East Asia, the Indian subcontinent, the former Soviet Union, and East Africa [11] .
Within the United Nations system, the directing and coordinating authority for public health in Middle East countries is the WHO Eastern Mediterranean Regional Office (EMRO), which is one of six regional offices. EMRO serves additional countries (has 21 member states and Palestine; West Bank and Gaza Strip; see: www.emro.who.int). Most of the available data on the burden of MDR TB within EMRO countries are based on WHO estimates, as no population-based representative surveys have been conducted yet in most of the countries. In most of the cases, data other than annual WHO reports are obtained from small studies that are designed to collect information from cases handled in referral hospitals, which makes these studies unreliable sources of data. In contrast, WHO estimates are based on modeling systems, and most of these contain discrepancies between the estimates and detection rates for each country [12, 13] .
TB profile of the Middle East
The methods used to estimate TB incidence in Middle East countries are variable. In countries such as Iran, Syria, Jordan, and Palestine, case notification data are combined with expert opinion about case detection gaps (under-reporting and underdiagnosis). In Turkey, Saudi Arabia, Qatar, Kuwait, and Oman, notifications are adjusted by a standard amount or measure of under-reporting from inventory studies (surveys conducted to quantify the level of under-reporting of detected TB cases, to account for case detection gaps). In Egypt, Iraq, and Yemen, recent capture-recapture studies were conducted (capture-recapture is a type of modeling designed to permit quantification of the level of underreporting of diagnosis of cases) [14] .
In 2014, a total of 58,252 TB cases were notified in the Middle East, and 96% of the cases were detected in seven countries (Iran, Iraq, Turkey, Egypt, Syria, Saudi Arabia, and Yemen). The biggest contributor to the TB burden in this region was Turkey, which comprised 22% of cases. Five countries reported a TB burden <25/100,000 population compared to one country in 1990 [13] , whereas two countries (Iraq and Yemen) reported a burden >50/100,000. Within the countries of the GCC in 2014, the total numbers of notified TB cases were 3,336 in Saudi Arabia, 743 in Kuwait, 465 in Qatar, 358 in Oman, and 61 in UAE. Bahrain did not report any data to WHO in 2014. The highest estimated incidence and prevalence were in Qatar (29 and 37 per 100,000 population, respectively) whereas the lowest were in UAE (1.6 and 2.7 per 100,000 population, respectively).
Brief history and definitions of drug resistance in Mycobacterium tuberculosis
Resistance to antimicrobials is a natural phenomenon, nevertheless, in M. tuberculosis, resistance to anti-TB drugs is considered ''man-made", as it commonly results from artificial selection of spontaneous drug resistance mutations during inadequate or incomplete therapy [15] [16] [17] . The development of resistance to anti-TB drugs was detected shortly after their introduction (streptomycin) in 1947 [18, 19] . Over the past 40 years, there has been an emergence and escalated recognition of several patterns of drug resistance in TB strains [15] [16] [17] . Currently, there is a consensus definition for two important drug-resistance patterns: MDR TB and extensively drugresistant (XDR) TB [15] [16] [17] . MDR TB is defined as resistance to at least isoniazid and rifampicin; the two most effective and less toxic first-line anti-TB drugs [20] [21] [22] . XDR TB is defined as MDR TB that also has resistance to at least a fluoroquinolone and one second-line injectable agent (amikacin, kanamycin, and/or capreomycin); the two most potent classes of secondline anti-TB drugs [23] [24] [25] [26] . The definitions of drug-resistance patterns are based on clinical, epidemiological, and laboratory data. These data are validated by several recognized laboratories. For instance, the XDR TB definition was chosen on the basis of data from 14 Supranational TB Reference Laboratories included drug susceptibility testing (DST) results of 18,225 patients collected from 48 countries in 2000-2004 [27] .
Over time, newer anti-TB drug resistance patterns have developed and spread. During the past 10 years, several published studies reported the emergence of strains that were shown to be resistant to all of the existing anti-TB drugs [23] [24] [25] [26] [27] [28] . These strains are hypothesized to be XDR TB, with resistance to additional second-line TB drugs [23] [24] [25] [26] . The definition of drug-resistance patterns of TB beyond XDR is controversial and subject to huge debate. In 2007, a new acronym (XXDR TB = extremely drug-resistant TB) was suggested to designate the resistance pattern in two isolates recovered from cases in Italy [23] . Those two ''XXDR-TB" cases were shown to resist all first-and second-line drugs. Two years later, a report from Iran was published describing the characterization of strains that were resistant all known anti-TB drugs [24] . The authors proposed the acronym totally drug-resistant (TDR) TB to denote this pattern of resistance. In 2012, a report from India described the isolation of TDR TB from Indian patients [25] . Nevertheless, there is ongoing debate on the selection of criteria to designate the level of TB drug resistance beyond XDR TB [29] .
Debate on TDR TB
The different authorities, including WHO, are hesitant to give definitions for resistance beyond XDR TB [30] [31] [32] . The reasons include issues surrounding reliability of the current DST methods; the expected negative impact of the word ''total" on patients, contacts, and caregivers; and the sufficiency of the available evidence and studies [31] . Furthermore, there are several new drugs that will be released shortly or in the foreseeable future, however, there is yet no reliable DST developed to test their susceptibility [30] . The reported TDR TB strains cannot be ignored as they are not only resistant to all available anti-TB drugs, but they are also morphologically distinct. On electron microscopy, those strains show variable morphological forms [33, 34] . The cell wall of the TDR TB strains is thicker than that of MDR TB strains with the appearance of pilus-like structures [35] [36] [37] . The need for further studies to precisely define the TDR TB strains is obvious. However, in comparison to the amount of data used to define XDR TB, there may be a need for more studies to dismiss or accept the definition TDR TB. In contrast, TDR TB may represent a dilemma in many clinical settings within Middle East countries. Considering the limited availability of drugs in certain geographic regions and the absence of laboratories able to test the susceptibility to additional anti-TB drugs, it would be convenient to use the acronym TDR TB in restricted geographic regions in which such strains are detected as the term reflects the actual therapeutic options.
Surveillance of drug resistance in TB in the Middle East
The most effective approach to monitor trends in drug resistance in new and previously treated TB cases is by applying continuous surveillance for MDR TB, through routine DST of TB patients and systematic collection and analysis of data [15] . Indeed, the extent of MDR/XDR TB globally was found to be much higher than previously expected [38] . However, the global awareness of the risk of spread of drug resistance patterns was mobilized late [39] . Internationally, an increasing number of countries have established high-quality surveillance systems to track drug resistance in TB. In resource-limited settings, routine DST is not accessible to all TB patients, due to lack of laboratory capacity or resources. This makes continuous surveillance for MDR TB through routine DST of TB patients impractical. The recommended alternative approach to the continuous surveillance for MDR TB, through routine DST of TB patients is by conducting surveys every 5 years to investigate the burden of drug resistance. Within Middle East countries, in 2014, the first-ever drugresistance survey was completed in Iraq and a repeat survey was completed in Iran [12] . Within Middle East countries, routine DST is not accessible to all patients. In Qatar, Oman, and Kuwait, the burden of TB is low, and therefore, all cases (new and retreatment) were tested for MDR TB. By contrast, in other countries, the proportion of tested cases was in the range from 1% to 84% within new cases and from 15% to 60% within the retreatment group of patients. Some countries such as Palestine did not test any cases [12] . Therefore, in many Middle East countries, substantial numbers of notified TB cases are not tested for MDR TB, and thus, unknown numbers of MDR TB cases are missed. This may contribute to the under-reporting of MDR TB in Middle East countries.
Epidemiology of MDR TB in the Middle East
Globally, an estimated 3.3% of new TB cases and 20% of previously treated cases have MDR TB; a level that has changed little in recent years [12] . Similarly, within EMRO countries, the proportion of MDR TB cases accounted for 3.2% and 18% of new and previously treated TB cases in 2014, respectively. The underdetection of MDR TB cases remains a serious challenge to TB control [40] . Underdetection mainly results from a low proportion of cases being tested for MDR TB [15, 40] . In 2014, only 4.6% of the new cases and 52% of the previously treated cases were tested for MDR TB.
In Turkey, several population-based and hospital-based studies have shown that the proportion of drug-resistant TB cases is higher than the global average [41] [42] [43] [44] [45] [46] . For instance, in a study using 397 M. tuberculosis clinical isolates collected from Malatya, Turkey, in the period from 2000 to 2007, resistance to any anti-TB drug was found in 29% (114 of 397) of the study isolates, while the MDR rate was approximately 4.5% (18 of 397). The 2012 report of fighting tuberculosis in Turkey [47] presented data on the rate of MDR TB cases in 2005, 2009, 2011, and 2012. In 2005, the reported number of MDR TB patients among newly diagnosed cases, was 101 (3.1%); the MDR TB rate in the retreatment cases was 17.7% (90 patients); and the MDR TB rate in all cases was 5.1% (191 patients). In 2009, it was reported that the number of MDR TB patients was 99 (2.7%) among newly diagnosed cases, and 123 (20.5%) in the retreatment cases, and the total number of MDR TB cases was 222 (5.1%) [47] . The rate of new MDR TB cases was 2.7% (116 people); that of previously treated patients was 24.3% (146 people); and that of all cases of MDR TB was 5.4% (262 people) in 2011. In 2012, the rate of new MDR TB cases was 3.2%; that of patients receiving prior treatment was 21.8% (140 people); and that of all cases was 5.4% (291 people). According to the WHO report of 2014, the percentage of estimated MDR TB within the new cases was 2.5% (2.1-3%) and within the retreatment group, it was 18% (15-21%). The estimated number of MDR TB cases among the notified pulmonary TB cases was 190 (160-230) and among the new cases and 170 (140-200) among the retreatment cases. However, the number of laboratory confirmed MDR TB cases was 349 cases, and 257 patients started on MDR TB treatment.
The WHO report of 2015, included the following data on MDR TB cases in Iran. The percentage of estimated MDR TB within the new cases was 0.8% (0.3-1.4%) and within the retreatment group it was 12% (6.2-19%). The estimated number of MDR TB cases among the notified pulmonary TB cases was 55 (21-96) and among the new cases, and 76 among the retreatment cases. However, there were 48 laboratory confirmed MDR TB cases and 53 patients started on MDR TB treatment. Within GCC countries, the estimated prevalence of MDR TB cases among new TB cases ranged from 1.7% in UAE to 6.3% in Bahrain, whereas estimated prevalence among retreated cases ranged from 0% in Kuwait and Oman to 16% in Saudi Arabia [12] . The study of Areeshi et al. [48] in 2014 discussed the prevalence of drug resistance in clinical isolates of M. tuberculosis from GCC countries based on review and analysis of reports published between January 2002 and March 2013. The study included 11,393 M. tuberculosis isolates from GCC countries. The highest prevalence rate of MDR TB was found in UAE (9.2%), followed by Kuwait (5.9%) and Saudi Arabia (4.3%). The overall MDR TB prevalence rate was recorded as 4.0% in the entire GCC region [48] . In Kuwait, Mokaddas et al. [49] in 2008 analyzed the incidence and trends of drug resistance among all M. tuberculosis strains isolated in Kuwait during a 10-year period, from 1996 to 2005. The MDR resistance rate was 0.9%, and the rate was almost stable over the 10-year period. Similar to other Gulf States, most TB cases were identified in expatriates. In Saudi Arabia, the first nationwide survey for MDR TB cases [50] allowed a comparison to be made between the WHO estimates, based on modeling work, and the nationwide survey. The WHO report of 2011 suggested that 1.2% (0.7-1.6%) and 9.0% (5.6-12.4%) of new and previously treated cases, respectively, were MDR TB [51] . However, the national survey showed MDR TB in 1.8% and 15.9% of new and previously treated TB cases, respectively. This survey confirms that the proportion of MDR TB in Saudi Arabia is low, although the rates were slightly higher than WHO estimates. In this survey, the strongest independent predictors of MDR TB were a treatment history of active TB, being foreign-born, having pulmonary TB, and living in the western part of the country. According to this survey, it seems that drug resistance is not a major problem in Saudi Arabia, where the proportion of MDR TB among newly diagnosed cases is among the lowest reported globally and in the WHO EMR. Indeed, MDR TB is not uniformly distributed throughout Saudi Arabia but rather is more concentrated in the western provinces and in the large population of immigrant workers.
Management of MDR TB and treatment outcomes in the Middle East
The WHO Working Group on DOTS-Plus for MDR TB was established in 1999 to lead the global effort to control the disease. DOTS-Plus is a case management strategy under the aegis of Directly Observed Treatment Short Course (DOTS to manage MDR TB encompassing two elements: first is the treatment of the MDR TB patients using second-line drugs; and second are the measures to control infection. Implementation of effective DOTS-Plus requires existing efficiently implemented DOTS [52] . The ultimate goals for the DOTS-Plus strategy are to reduce morbidity and mortality from MDR TB, as well as to cut the chain of transmission [53] . To ensure that the DOTS-Plus strategy is implemented effectively, the WHO Working Group on DOTS-Plus established a Green Light Committee (GLC) in June 2000 to lay down the ''Models of Good Practice" for MDR TB patients. This committee ensures that benchmarks are met before DOTS-Plus is initiated at any site and also provide technical support for implementing DOTS-Plus protocols. One major function of this committee is to collaborate with second-line drug manufacturers to maintain a continuous supply of quality-assured drugs at affordable rates [54] . Countries that meet the framework requirements, with a strong DOTS foundation and a solid plan to manage drug-resistant TB, can benefit from quality-assured second-line drugs at reduced prices. The GLC also offers technical assistance before implementation of drug-resistant TB control programs and monitors approved projects.
By 2015, 10 of the Middle East countries reported outcomes for a total of 522 notified MDR TB cases started on treatment in 2012. The country cohort size ranged from two to 291 cases. Six countries reported outcomes for >10 MDR TB cases per country. The treatment success rates were in the range from 20% in Saudi Arabia to 66% in Turkey. The number of cases reported in annual cohorts has steadily increased. Except for Saudi Arabia, the proportion of failures, defaulters, and deaths are comparable with the average treatment success rate reached within the GLC projects and with other reported studies [12] .
In a retrospective study in Iran, all MDR TB patients hospitalized at a tertiary hospital in Tehran, Iran, during 2004-2007 were recruited. Fifty-one patients were included, 12 with XDR TB criteria. Successful outcome was 81.2% in patients with MDR TB in comparison with 41.6% in patients with XDR TB [55] .
The study of Gadallah et al. [56] in 2015 represents the first Egyptian national treatment cohort of MDR TB from 2006 to 2010. In this cohort, the number of laboratory-confirmed MDR TB cases was 228; of which, 225 were pulmonary cases. A total of 158 (119 cured and 39 completed treatment) patients achieved a successful outcome (69.3%), 16 (7.1%) failed treatment, 27 (11.8%) were lost to follow-up, and 27 (11.8%) died. Predictors of unsuccessful outcome were delay in sputum culture conversion to P2 months, moderate or extensive lung lesions, and a history of diabetes [56] .
Second-line DST
Owing to the increased proportion of XDR TB cases detected globally, patients with MDR TB require DST for second-line drugs to refine and optimize their treatment regimen. Indeed, one of the targets included in the Global Plan to Stop TB 2011-2015 was that by 2015, all patients with MDR TB would be tested for XDR TB [14] . However, this target seemed far from being achieved in most of the Middle East countries due to the lack of capacity to perform second-line DST. Iran, Egypt, Oman, Turkey, and UAE have built in-country capacity for second-line DST, whereas Iraq, Qatar, Lebanon, and Palestine rely on partner laboratories outside the country (including WHO Supranational Reference Laboratories) for such testing. However, Kuwait, Jordan, Saudi Arabia, Syria, and Yemen with reported MDR TB cases indicated that they had neither in-country capacity nor a linkage with a partner laboratory for second-line DST [12] .
Epidemiology of XDR-TB in the Middle East
The first description of XDR TB cases was in 2006 by the US Centers for Disease Control and Prevention [57] . A serious nosocomial outbreak of XDR TB was identified in 2005 at the Church of Scotland Hospital in Kwazulu-Nata, Tugela Ferry, South Africa. The strains responsible for this outbreak were rapidly fatal with a mortality rate of 98% [58] . By the end of 2014, 105 countries had reported cases of XDR TB. The average percentage of XDR TB cases among MDR TB cases was 9.7%. A total of 49 countries and territories are reported to treating people with XDR TB [12] .
Within the Middle East, several countries have documented the existence of XDR TB cases. In Turkey, nine XDR TB cases were reported in the period from 2010 to 2012. Three of these patients were born in Turkey, while the other three were born outside of Turkey [47] . Within the GCC, only Oman has reported data on XDR TB; reporting four cases of XDR TB that started second-line treatment in 2012, and by 2014, only two showed treatment success. In Iran, XDR cases are frequently reported [55, 59, 60] . The study of Masjedi et al. [59] represents 2 years surveillance in a tertiary health center to determine the existence and transmission of XDR TB among patients with MDR TB in Iran. In that study, testing of susceptibility to first-line drugs for 1284 M. tuberculosis isolates revealed the existence of 113 MDR TB cases. Susceptibility testing of the MDR TB strains for second-line drugs showed the presence of 12 (10.9%) XDR TB cases. They performed genotypic investigations to figure out the genetic relatedness among the XDR TB isolates and found that all of them belonged to one of two epidemiological clusters: either a single-family cluster (4 cases) or a cluster of close contacts (8 cases) . In either of the two clusters, the index patients acquired the XDR TB strains from an individual infected by MDR TB strains and transmitted it to their contacts [59] .
Management of XDR TB patients
Treatment of XDR TB patients is problematic and frequently requires at least 18-24 months of four to six second-line anti-TB drugs. Globally, a total of 49 countries and territories are reported to be treating people with XDR TB, and 41 countries reported outcomes for cohorts from 2012. In those cohorts, there were 2685 XDR TB patients. A total of 682 (26%) had completed treatment successfully; 809 (30%) died; treatment failed for 510 (19%); and 684 (25%) were lost to follow-up or their treatment outcome was not evaluated [12] . This low global success rate in treating XDR TB indicates the urgent need for more effective regimens. Within EMRO countries, there were 43 XDR TB cases started on second-line treatment in 2012, which showed a treatment success rate of 33%.
Within Middle East countries, only three countries are reporting outcomes of treatment of XDR TB cases: Turkey, Iran, and Oman. In 2015, Turkey and Oman reported the treatment outcomes of eight XDR TB cases that started treatment in 2012. In Turkey, the cohort included six cases, and four of them completed treatment successfully. In Oman, the cohort comprised two cases, and one was treated successfully [12] . This treatment success rate is higher than the global rate. In Iran, the report of Tabarsi et al. [55] discussed the treatment outcome of MDR non-XDR TB (39 patients) and XDR TB (12 patients) from 2004 to 2007. The treatment success rate was 87.2% in the MDR non-XDR TB cases, whereas it dropped to 41.7% in the XDR TB cases.
Application of molecular methods for rapid diagnosis of drug resistance in the Middle East
Clearly, there is under-reporting of MDR/XDR TB cases in Middle East countries. One reason for this is the limited capacity of the infrastructure to provide widespread coverage of DST services. The use of molecular methods and technologies is a potential alternative to conventional DST, especially at lower levels of the health system. Over the past 20 years, sev-eral molecular methods and technologies were evaluated for the rapid identification of MDR/XDR TB cases in the Middle East [61] [62] [63] [64] [65] [66] [67] . Two rapid molecular assays were endorsed by WHO for diagnosis of TB and drug resistance: line-probe assays and Xpert MTB/RIF. At present, the real-time polymerase chain reaction assay for rifampin resistance, Xpert MTB/RIF test (Cepheid, Sunnyvale, CA, USA), is the only mature fully automated technology that has the ability to perform simultaneous detection of TB and resistance to rifampicin [14] . The utility of both technologies was reported in several field and experimental studies [68] . In 2010, WHO recommended the use of Xpert MTB/RIF for initial diagnosis of patients suspected to have MDR TB or HIV-associated TB (strong recommendations) [51] . After being endorsed and recommended by WHO, the use of Xpert MTB/RIF has been quickly expanded within many countries. By the end of December 2014, WHO data showed that a total of 3763 Xpert devices had been introduced into the public services in 116 of the 145 countries entitled for concessional pricing [12] . Field studies have documented the positive impact of Xpert expansion in improving case-finding and detection of drug resistance [69] .
Despite the WHO recommendation for the use of Xpert MTB/RIF technology and its expanded usages, a limited number of Middle East countries have purchased this technology. Turkey and Iraq have the highest number of registered site performing Xpert MTB/RIF (24 and 11 sites, respectively). Iran has three sites and Jordan has a single site. The other Middle East countries have not yet any registered site performing this technology. Surprisingly, none of the GCC countries has reported or registered a site to perform Xpert MTB/RIF. While some countries cannot afford to use Xpert MTB/RIF, due to economic crises, such as in Yemen and Syria, it is not clear why other wealthy countries have not yet introduced this technology.
Conclusion
There is obvious under-reporting of MDR/XDR TB cases in the Middle East. The low coverage of DSTwithin many of the Middle East countries is one of the main constraints limiting the detection of MDR TB among people diagnosed with TB. Only a small proportion of new bacteriologically confirmed TB cases, as well as those treated for TB, were tested for MDR TB. This indicates that access to TB laboratory services within Middle East countries is low and below the target envisaged by WHO planning. Expanding the coverage of diagnostic DST is an immediate requirement to enhance the detection of MDR and XDR TB. 
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